Evidence map›Paper›PMID 29464544›Full record

ArticleJournal of the American Society for Mass Spectrometry2018

Top Down Tandem Mass Spectrometric Analysis of a Chemically Modified Rough-Type Lipopolysaccharide Vaccine Candidate.

Benjamin L Oyler, Mohd M Khan, Donald F Smith, Erin M Harberts, David P A Kilgour, Robert K Ernst, Alan S Cross, David R Goodlett

Erratum issuedAbstract read
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Benjamin L OylerSchool of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Mohd M KhanSchool of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Donald F SmithNational High Magnetic Field Laboratory, Florida State University, Tallahassee, FL, 32310, USA.
Erin M HarbertsDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD, 21201, USA.
David P A KilgourChemistry and Forensics, School of Science and Technology, Nottingham Trent University, Nottingham, NG11 8NS, UK.
Robert K ErnstDepartment of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD, 21201, USA.
Alan S CrossCenter for Vaccine Development, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
David R GoodlettDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Pharmacy Hall North Room 623, 20 N. Pine St, Baltimore, MD, 21201, USA. dgoodlett@rx.umaryland.edu.

Funding

Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural VariantsR01AI123820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ERNST, ROBERT K, GOODLETT, DAVID ROBINSON · 2016 to 2019
$1.5M
National Institute of Allergy and Infectious Diseases 5R01AI123820National Science Foundation DMR-1157490NIAID NIH HHS R01 AI123820
6 · The paper itself

Abstract

Recent advances in lipopolysaccharide (LPS) biology have led to its use in drug discovery pipelines, including vaccine and vaccine adjuvant discovery. Desirable characteristics for LPS vaccine candidates include both the ability to produce a specific antibody titer in patients and a minimal host inflammatory response directed by the innate immune system. However, in-depth chemical characterization of most LPS extracts has not been performed; hence, biological activities of these extracts are unpredictable. Additionally, the most widely adopted workflow for LPS structure elucidation includes nonspecific chemical decomposition steps before analyses, making structures inferred and not necessarily biologically relevant. In this work, several different mass spectrometry workflows that have not been previously explored were employed to show proof-of-principle for top down LPS primary structure elucidation, specifically for a rough-type mutant (J5) E. coli-derived LPS component of a vaccine candidate. First, ion mobility filtered precursor ions were subjected to collision induced dissociation (CID) to define differences in native J5 LPS v. chemically detoxified J5 LPS (dLPS). Next, ultra-high mass resolving power, accurate mass spectrometry was employed for unequivocal precursor and product ion empirical formulae generation. Finally, MS

Indexed as

Cell LineEscherichia coliEscherichia coli InfectionsEscherichia coli VaccinesHumansLipopolysaccharidesTandem Mass SpectrometryEscherichia coli VaccinesLipopolysaccharidesCollision induced dissociationFT-ICRLipid ALipopolysaccharideOligosaccharideTop downVaccine

Identifiers

PMID29464544
PMCPMC8294406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.